Incidence-based cost estimates require population-based incidence data. A critique of Mahan et al.

• References

• 1 Mahan CE, Holdsworth MT, Welch SM. et al. Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event. Thromb Haemost 2011; 106: 405-415.
• 2 Grosse SD.. Economic evaluations of newborn screening interventions. In: Ungar WJ. (ed). Economic Evaluation in Child Health. Oxford University Press; 2009: 113-132.
• 3 Heit JA, O’Fallon WM, Petterson TM. et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 1245-1248.
• 4 Spencer FA, Emery C, Lessard D. et al. The Worcester Venous Thromboembolism Study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-727.
• 5 White RH.. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-8.
• 6 Braekkan SK, Mathiesen EB, Njølstad I. et al. Family history of myocardial infarction is an independent risk factor for venous thromboembolism: the Tromsø study. J Thromb Haemost 2008; 06: 1851-1857.
• 7 Naess IA, Christiansen SC, Romundstad P. et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 05: 692-699.
• 8 Cushman M, Tsai AW, White RH. et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004; 117: 19-25.
• 9 Heit JA, Mohr DN, Silverstein MD. et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000; 160: 761-768.
• 10 Spencer FA, Gore JM, Lessard D. et al. Patient outcomes after deep vein thrombosis and pulmonary embolism: the Worcester Venous Thromboembolism Study. Arch Intern Med 2008; 168: 425-430.
• 11 Prandoni P, Lensing AW, Cogo A. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 12 Douketis JD, Gu CS, Schulman S. et al. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med 2007; 147: 766-774.
• 13 Centers for Disease Control and Prevention. National Center on Birth Defects and Developmental Disabilities Strategic Plan 2011-2015. Available at: http://www.cdc.gov/NCBDDD/AboutUs/documents/NCBDDD_StrategicPlan_2–10–11.pdf Accessed September 12, 2011.
• 14 Raskob G, Silverstein R, Bratzler D. et al. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med 2010; 38: S502-S509.
• 15 Beckman MG, Grosse SD, Kenney KM. et al. Developing surveillance activities for deep vein thrombosis and pulmonary embolism. Am J Prev Med 2011; 41: S428-S434.
• 16 White RH, Zhou H, Murin S. et al. Effect of ethnicity and gender on the incidence of venous throm-boembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93: 298-305.
• 17 Stein PD, Kayali F, Olson RE. et al. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med. 2004; 116: 435-442.
• 18 James AH, Jamison MG, Brancazio LR. et al. Venous thromboembolism during pregnancy and the post-partum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006; 194: 1311-1315.
• 19 Heit JA, Beckman MG, Bockenstedt PL. et al. Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol 2010; 85: 467-471.
• 20 Sørensen HT, Riis AH, Diaz LJ. et al. Familial risk of venous thromboembolism: a nationwide cohort study. J Thromb Haemost 2011; 09: 320-324.
• 21 Severinsen MT, Johnsen SP, Tjønneland A. et al. Body height and sex-related differences in incidence of venous thromboembolism: a Danish follow-up study. Eur J Intern Med 2010; 21: 268-272.
• 22 Holst AG, Jensen G, Prescott E.. Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 2010; 121: 1896-1903.
• 23 U.S. Department of Health and Human Services. The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism. 2008
• 24 Beckman MG, Hooper WC, Critchley SE. et al. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38: S495-S501.
• 25 Spencer FA, Lessard D, Emery C. et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167: 1471-1475.
• 26 Maynard GA, Morris TA, Jenkins IH. et al. Optimizing prevention of hospital-acquired venous thromboembolism (VTE): prospective validation of a VTE risk assessment model. J Hosp Med 2010; 05: 10-18.
• 27 Kucher N, Koo S, Quiroz R. et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 969-977.
• 28 Novis SJ, Havelka GE, Ostrowski D. et al. Prevention of thromboembolic events in surgical patients through the creation and implementation of a computerized risk assessment program. J Vasc Surg. 2010; 51: 648-654.
• 29 Cronin M, Hill T, Reich DA. et al. Implementation of a multidisciplinary, pharmacy-led, thromboprophylaxis program in total-joint arthroplasty patients. Am J Health Syst Pharm 2009; 66: 171-175.
• 30 Mahan CE, Spyropoulos AC.. Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient. Hosp Pract (Minneap) 2010; 38: 97-108.
• 31 Amin A, Hussein M, Battleman D. et al. Appropriate VTE prophylaxis is associated with lower direct medical costs. Hosp Pract (Minneap) 2010; 38: 130-137.
• 32 Biffl WL, Beno M, Goodman P. et al. „Leaning” the process of venous thromboembolism prophylaxis. Jt Comm J Qual Patient Saf. 2011; 37: 99-109.
• 33 Amin AN, Lin J, Johnson BH. et al. Clinical and economic outcomes with appropriate or partial prophylaxis. Thromb Res. 2010; 125: 513-517.